Cognitive Impairment in Older Adults With Hematologic Malignancies
Prevalence of Cognitive Impairment and Its Association With Activities of Daily Living Among Older Adults With Hematologic Malignancies Receiving Chemotherapy
This cross-sectional study aims to determine the prevalence of cognitive impairment and evaluate its relationship with activities of daily living among older adults with hematologic malignancies receiving chemotherapy.
調査の概要
詳細な説明
Cognitive impairment is common among older adults with cancer and may affect treatment adherence and independence. This observational study will include adults aged 65 years or older with confirmed hematologic malignancies who are currently receiving chemotherapy.
Participants will undergo cognitive assessment using the Montreal Cognitive Assessment (MoCA) and functional assessment using the Katz Index of Activities of Daily Living (ADL) and Lawton Instrumental Activities of Daily Living (IADL).
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前：Kholoud K Fawzy, Resident
- 電話番号：01009850621
- メール：khloud.18313604@med.aun.edu.eg
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Older adults aged 65 years or older with confirmed hematologic malignancies receiving chemotherapy at Assiut University Hospitals.
説明
Inclusion Criteria:
- - Age 65 years or older
- Confirmed diagnosis of hematologic malignancy
- Currently receiving chemotherapy
- Able to communicate and participate in cognitive assessment
- Written informed consent
Exclusion Criteria:
- - Previously diagnosed dementia before the diagnosis of malignancy
- Delirium at the time of assessment
- Severe visual or hearing impairment interfering with cognitive testing
- History of major neurological disorders affecting cognition
- Severe psychiatric illness affecting cognitive assessment
- Critically ill patients unable to complete study assessment
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 観測モデル：CASE_ONLY
- 時間の展望：CROSS_SECTIONAL
コホートと介入
グループ/コホート |
|---|
|
Single cohort: Older adults with hematologic malignancies
Adults aged 65 years or older with hematologic malignancies receiving chemotherapy who will undergo cognitive and functional assessment. |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Prevalence of cognitive impairment
時間枠：Baseline
|
Proportion of participants with cognitive impairment defined as a Montreal Cognitive Assessment (MoCA) score less than 26. |
Baseline
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Mean MoCA score
時間枠：Baseline
|
Mean Montreal Cognitive Assessment (MoCA) score (range 0-30, higher scores indicate better cognition).. |
Baseline
|
|
Mean Katz ADL score
時間枠：Baseline
|
Mean Katz Index of Independence in Activities of Daily Living score (range 0-6, higher scores indicate greater independence). |
Baseline
|
|
Mean Lawton IADL score
時間枠：Baseline
|
Mean Lawton Instrumental Activities of Daily Living score (range 0-8, higher scores indicate greater independence) |
Baseline
|
|
Proportion with impaired activities of daily living
時間枠：Baseline
|
Proportion of participants with impaired Katz ADL score. |
Baseline
|
|
Proportion with impaired instrumental activities of daily living
時間枠：Baseline
|
Proportion of participants with impaired Lawton IADL score. |
Baseline
|
協力者と研究者
スポンサー
捜査官
- スタディチェア：Soher M kasem, prof、Internal Medicine Department, Assiut University Hospitals
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。